Corticotrophin-releasing hormone (CRH) exerts differentiating activity toward human endometrial cells mediated by CRH-R1 receptors. The gene expression and biosynthesis of CRH have also been demonstrated in Ishikawa(IK) cells a tumor cell line derived from human endometrium. CRH exhibit an anti-proliferative effect on IK cells expressing CRH-R1. We tested whether Cortagine, a newly developed selective CRH-R1 peptide agonist, can also regulate IK cells growth. MATERIALS AND METHODS: The cells were treated with graded concentration of Cortagine (10-7-10-10M) and with medium alone or containing drug solvent, were than incubated at 37 C for 5 days, adding the peptide each day. Cell growth was evaluated every 24h by counting cells in quadruplicate. Cell proliferation was also assessed with the MTS Cell Proliferation Assay kit according to the manufacturer’s instructions, an assay based on the measurement of cell metabolism. RESULTS: Cortagine was able to inhibit cell proliferation, with respect to untreated or vehicle-treated controls, in a time- and dose-dependent manner. CRH growth inhibitory activity was con rmed using MTS assay. The maximum inhibition was observed with Cortagine 100 nM, the same concentration signi cantly inhibited cell growth after 48 and 72 h of incubation. CONCLUSION: In conclusion, here we have demonstrated an anti-proliferative effect of Cortagine on Ishikawa tumor cells, accordingly with our previous results obtained with CRH. The relevance of the present ndings in human pathology needs to be further veri ed since CRH-R1 agonists could be evaluated as inhibitors of tumor cell proliferation in human endometrial cancer therapy.
Miceli, F., Muzi, A., Cantalupo, E., Pozzoli, G., Graziani, G., Navarra, P. (2011). Cortagine, a Selective CRH-R1 Agonist, Inhibits Cell Proliferation of Human Endometrial Adenocarcinoma Cells. ??????? it.cilea.surplus.oa.citation.tipologie.CitationProceedings.prensentedAt ??????? 58th Annual Scientific Meeting Reproductive Scieneces, Miami, FL, USA.
Cortagine, a Selective CRH-R1 Agonist, Inhibits Cell Proliferation of Human Endometrial Adenocarcinoma Cells
GRAZIANI, GRAZIA;
2011-01-01
Abstract
Corticotrophin-releasing hormone (CRH) exerts differentiating activity toward human endometrial cells mediated by CRH-R1 receptors. The gene expression and biosynthesis of CRH have also been demonstrated in Ishikawa(IK) cells a tumor cell line derived from human endometrium. CRH exhibit an anti-proliferative effect on IK cells expressing CRH-R1. We tested whether Cortagine, a newly developed selective CRH-R1 peptide agonist, can also regulate IK cells growth. MATERIALS AND METHODS: The cells were treated with graded concentration of Cortagine (10-7-10-10M) and with medium alone or containing drug solvent, were than incubated at 37 C for 5 days, adding the peptide each day. Cell growth was evaluated every 24h by counting cells in quadruplicate. Cell proliferation was also assessed with the MTS Cell Proliferation Assay kit according to the manufacturer’s instructions, an assay based on the measurement of cell metabolism. RESULTS: Cortagine was able to inhibit cell proliferation, with respect to untreated or vehicle-treated controls, in a time- and dose-dependent manner. CRH growth inhibitory activity was con rmed using MTS assay. The maximum inhibition was observed with Cortagine 100 nM, the same concentration signi cantly inhibited cell growth after 48 and 72 h of incubation. CONCLUSION: In conclusion, here we have demonstrated an anti-proliferative effect of Cortagine on Ishikawa tumor cells, accordingly with our previous results obtained with CRH. The relevance of the present ndings in human pathology needs to be further veri ed since CRH-R1 agonists could be evaluated as inhibitors of tumor cell proliferation in human endometrial cancer therapy.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.